The Allergic Conjunctivitis drugs in development market research report provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Allergic Conjunctivitis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued products.

GlobalData tracks 26 drugs in development for Allergic Conjunctivitis by 26 companies/universities/institutes. The top development phase for Allergic Conjunctivitis is preclinical with nine drugs in that stage. The Allergic Conjunctivitis pipeline has 26 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Allergic Conjunctivitis pipeline products market are: IACTA Pharmaceuticals, Zhaoke (Guangzhou) Ophthalmology Pharmaceutical and Siolta Therapeutics.

The key targets in the Allergic Conjunctivitis pipeline products market include Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC, Histamine H1 Receptor (HRH1), and Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4).

The key mechanisms of action in the Allergic Conjunctivitis pipeline product include Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC Inhibitor with four drugs in Phase II. The Allergic Conjunctivitis pipeline products include seven routes of administration with the top ROA being Ophthalmic and eight key molecule types in the Allergic Conjunctivitis pipeline products market including Small Molecule, and Monoclonal Antibody.

Allergic Conjunctivitis overview

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) becomes swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye, and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

For a complete picture of Allergic Conjunctivitis’s pipeline drug market, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.